Alina Buture
A5071458657- Migraine and Headache Studies
- Sympathectomy and Hyperhidrosis Treatments
- Trigeminal Neuralgia and Treatments
- Venous Thromboembolism Diagnosis and Management
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cerebral Venous Sinus Thrombosis
- Ophthalmology and Eye Disorders
- Systemic Sclerosis and Related Diseases
- Botulinum Toxin and Related Neurological Disorders
- Blood Coagulation and Thrombosis Mechanisms
- Body Image and Dysmorphia Studies
- Cardiovascular Syncope and Autonomic Disorders
- Neurofibromatosis and Schwannoma Cases
- Cardiovascular Function and Risk Factors
- Vestibular and auditory disorders
- Intracerebral and Subarachnoid Hemorrhage Research
- Cardiovascular Disease and Adiposity
- Dermatologic Treatments and Research
- Biotin and Related Studies
- Vascular Malformations Diagnosis and Treatment
- Hallucinations in medical conditions
- Psychosomatic Disorders and Their Treatments
- Medical and Biological Sciences
- Meningioma and schwannoma management
- Facial Rejuvenation and Surgery Techniques
Mater Misericordiae University Hospital
2021-2024
Hull York Medical School
2019-2021
University of Hull
2019-2021
University Teaching Hospital
2020
Beaumont Hospital
2020
University of York
2020
Hull Royal Infirmary
2015-2019
<h3>Importance</h3> Thrombosis with thrombocytopenia syndrome (TTS) has been reported after vaccination the SARS-CoV-2 vaccines ChAdOx1 nCov-19 (Oxford–AstraZeneca) and Ad26.COV2.S (Janssen/Johnson & Johnson). <h3>Objective</h3> To describe clinical characteristics outcome of patients cerebral venous sinus thrombosis (CVST) without TTS. <h3>Design, Setting, Participants</h3> This cohort study used data from an international registry consecutive CVST within 28 days included between March...
Objective Cerebral venous thrombosis (CVT) caused by vaccine‐induced immune thrombotic thrombocytopenia (VITT) is a rare adverse effect of adenovirus‐based severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) vaccines. In March 2021, after autoimmune pathogenesis VITT was discovered, treatment recommendations were developed. These comprised immunomodulation, non‐heparin anticoagulants, and avoidance platelet transfusion. The aim this study to evaluate adherence these its association...
Many migraine patients do not respond adequately to conventional preventive treatments and are therefore described as treatment/medically resistant or difficult treat cases. Calcitonin gene-related peptide monoclonal antibodies a relatively novel molecular treatment for episodic chronic that have been shown be effective in short duration clinical trials approximately 40-50% of all patients. Patient Related Outcome Measures (PROM) Quality Life (QoL) questionnaires used help measure response...
Chronic migraine affects 2 % of the population and has substantial impact on quality life considerable burden healthcare resources. 50–80 patients with chronic have excessive consumption analgesic medications. Withdrawal analgesics is often advised before commencing preventive treatments. However, some headache experts recommend treatments alongside withdrawal. 434 attending Hull Headache Clinic who received OnabotulinumtoxinA as treatment were stratified to those or without overuse. Data...
Introduction: Previous reports and meta-analyses derived from small case series reported a mortality rate of up to 40% in patients with coronavirus disease 2019 associated cerebral venous thrombosis (COVID-CVT). We assessed the clinical characteristics outcomes an international cohort COVID-CVT. Patients methods: This was registry study consecutive COVID-CVT diagnosed between March 2020 2023. Data collected by International Cerebral Venous Thrombosis Consortium CVT 2017 2018 served as...
Abstract Raynaud's phenomenon is a rare side effect of CGRP monoclonal antibodies. These molecular treatments are relatively new class drugs for the prevention migraine. It likely that we will see this more often in future. Patients with background may experience worsening their symptoms if started on these treatments.
Patients diagnosed with New Daily Persistent Headache and Post-Traumatic belong to a heterogeneous group of primary secondary headache disorders, the common clinical feature that these conditions start abruptly, continue unabated, are refractory conventional migraine preventive treatments.This is real-world, medium-term audit explore whether erenumab improves quality life in pooled 82 abrupt-onset, unremitting treatment patients, where diagnosis new daily persistent post-traumatic majority...
Adenovirus-based COVID-19 vaccines are extensively used in low- and middle-income countries (LMICs). Remarkably, cases of cerebral venous sinus thrombosis due to vaccine-induced immune thrombotic thrombocytopenia (CVST-VITT) have rarely been reported from LMICs.We studied the frequency, manifestations, treatment, outcomes CVST-VITT report data an international registry on CVST after vaccination. VITT was classified according Pavord criteria. We compared LMICs high-income (HICs).Until August...
Cerebral venous sinus thrombosis associated with vaccine-induced immune thrombotic thrombocytopenia (CVST-VITT) is a severe disease high mortality. There are few data on sex differences in CVST-VITT. The aim of our study was to investigate the presentation, treatment, clinical course, complications, and outcome CVST-VITT between women men.We used from an ongoing international registry VITT diagnosed according Pavord criteria. We compared characteristics men.Of 133 patients possible,...
Cluster headache is a severe primary with similar prevalence to that of multiple sclerosis. characterised by unilateral trigeminal distribution pain, ipsilateral cranial autonomic features, and tendency circadian circannual periodicity.To explore the perceptions, experiences, understandings cluster among GPs neurologists.Qualitative interview study in care surgeries neurology departments north England.Semi-structured interviews were conducted neurologists, recorded, transcribed. A thematic...
Cluster headache (CH), a severe primary headache, is often misdiagnosed and mismanaged. The aim of this study was to develop evaluate screening tool aid the diagnosis CH. We developed novel 12-item tool. This comprised four components: (1) images depicting pain; (2) pain descriptors; (3) key questions that could differentiate between CH migraine; (4) visual analogue scale. total possible questionnaire score ranged from 3-32. Patients with migraines (control group) were recruited...
Objective: The objective of this prospective audit was to determine the long term outcome patients diagnosed with chronic migraine who were treated onabotulinumtoxinA for prevention migraine. Background: While and real-world studies have confirmed safety efficacy in CM, there remains limited information from large patient numbers on number cycles duration needed successfully convert episodic migraine, development resistance treatment sustainability response after stopping treatment. Methods:...
The diagnosis of primary headaches is based on the International Classification Headache Disorders (ICHD-3). Cluster headache (CH), a debilitating headache, often misdiagnosed as migraine. In absence biological markers, new visual screening tool with images depicting pain could aid correct CH. objective study to test healthy participants and CH migraine.In phase 1, 6 portraying people were tested 150 participants. asked rate mild, moderate, severe or excruciating pain. 2, further 116 (16 CH,...
Abstract Objective The objective of this prospective analysis was to determine the long-term outcome patients diagnosed with chronic migraine who were treated OnabotulinumtoxinA for prevention migraine. Background outcomes remains uncertain, including information on number cycles and duration needed successfully convert episodic migraine, development resistance treatment sustainability response after stopping treatment. Methods A total 655 adult received at Hull Migraine Clinic followed up...
The case of a 45 year old female with chronic migraine undergoing treatment erenumab 70 mg subcutaneous injection who developed Raynaud’s phenomenon (RP) as side effect relevant clinical implications two weeks after the second dose injection.